Published in Women's Health Weekly, March 16th, 2006
"Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1).
"HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks," scientists in the United States report.
According to D.C. Johnson and colleagues at Sinai Children's Hospital and Rosalind Franklin University of Medicine and Science in North Chicago, "The vaccines were safe. Lymphoproliferative...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.